Redeye comments on Klaria Pharma’s Q2 2023 report. Despite the recent rights issue at the end of 2022, which generated SEK59.2m in gross proceeds, we note that the company needs to strengthen its cash position before the year-end. While we anticipate a rights issue around year-end, we highlight the possibility of capital injections via its partnerships and/or a licensing agreement with its sumatriptan alginate film, which could fully or partially offset the need for a dilutive equity raise.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Klaria Pharma Q2 - Focus on sealing the deal

© Modular Finance, source Nordic Press Releases